Modifies provisions relating to the administration of medications by pharmacists
The impact of SB1126 on state laws is significant as it enhances the role of pharmacists in medication therapy management. Specifically, the bill allows licensed pharmacists to administer medications after completing board-approved training and gaining certification. Additionally, it clarifies the role of the state board of pharmacy and the Department of Health and Senior Services in overseeing pharmacy operations and medication management within hospitals. This aligns pharmacy practice with national trends that seek to empower pharmacists as healthcare providers.
Senate Bill 1126 aims to modify provisions concerning the administration of medications by pharmacists in Missouri. The bill proposes the repeal of sections 338.010 and 338.165 of the Revised Statutes of Missouri, replacing them with three new sections. The new provisions are intended to provide pharmacists with increased authority to order and administer medications, particularly during public health emergencies, subject to established protocols and guidelines set by the Department of Health and Senior Services.
Furthermore, SB1126 mandates that pharmacists administer vaccines under specific protocols compliant with CDC guidelines. This requirement aims to enhance public confidence in vaccine administration while ensuring that pharmacists remain appropriately trained for such tasks. This change could lead to improved public health outcomes, particularly during health crises, but may face pushback from those wary of expanding pharmacist responsibilities.
A notable area of contention surrounding SB1126 is the balance of authority between pharmacists and physicians. Proponents argue that it allows pharmacists to respond proactively to public health needs, including vaccination efforts and emergency medication distribution. However, there are concerns about pharmacists overstepping their bounds, particularly regarding the ability to prescribe or diagnose medications without physician consent. The bill explicitly restricts pharmacists from making therapeutic substitutions without a physician's directive, ensuring continued collaboration between healthcare providers.